



# BIOE688 - Bioethics in China: *Research, Industry, and Practice*

**August 24 - September 4, 2012**

In 2011, China issued its 12th 5-year plan, which characterizes biotechnology and pharmaceuticals as emerging battlegrounds where countries will be competing for technological leadership during the next wave of development. Understanding and navigating the emerging regulatory environment, cultural and ethical challenges will be critical to competitiveness. This course will provide executive students a broad understanding of bioethical issues in China, specifically:

- Challenges in conducting business and research in China, including organizational practices and business ethics.
- Ethical considerations in outsourcing clinical trials to China
- Pharmaceutical marketing practices in China
- Physician-Patient interactions and the notions of autonomy
- Ethics in health policy
- Intellectual property and the regulatory landscape in China



Students will travel to Beijing, Nanjing and Shanghai (August 24-September 4) where the program will include site visits, academic lectures, and meetings with policy makers, Chinese and expatriate business leaders and others. Visits to significant cultural sites will also be included. Class meetings will be held prior to and following the trip to China and will include distinguished guest speakers from the US and abroad.

Class size limited to 14 students. Due to the limited size of the course, interested pharmaceutical industry professionals should send their CV/Resume and a 1 page letter of interest to [MBEchina@mail.med.upenn.edu](mailto:MBEchina@mail.med.upenn.edu). Students will be selected by committee.

Confirmed guest speakers include: **Daofen Chen, PhD**, Program Director at NIH, **Qian Chen, MD**, Deputy Director, IRB, Associate Professor, Hospital 301, **David Cragin, PhD**, Professor of International Pharmaceutical Engineering Management at Peking University, Adjunct Prof of Health Policy at University of the Sciences in Philadelphia, **Roxanne Duan, PhD**, Director, External Discovery and Scientific Operation at Glaxo-SmithKline R&D-China, **Seth Goldberg, PhD**, President of Asia Pacific Bio Intelligence, **Lily Lee, PhD**, Vice President, Johnson & Johnson and founding R&D Head of Xian-Janssen, **Jane Lin, MD, MPH**, Vice President, Regulatory Affairs and Clinical Development, Wuxi AppTech, **Bradley Marchant, MD**, Senior Director and Head of Clinical Development, Asia-Pacific R&D at Sanofi, **Wendy Pan, JD, PhD**, Counsel at O'Melveny & Myers, LLP, **Joan Shen, MD, PhD**, Senior Medical Director and Clinical Lead at Pfizer-China, **Jingsong Wang, MD, PhD**, Head of China R&D and Head of Translational Research Asia-Pac at Sanofi-China, **Helen Yang, MBA**, Director, Public Affairs and Policy, Emerging Markets - Asia, Pfizer, **Steve Yang, PhD**, Vice President and Head of R&D, Asia and Emerging Markets at AstraZeneca, **Xiaomei Zhai, PhD**, Executive Director, Center for Bioethics, Chinese Academy of Medical Sciences and the Peking Union Medical College, **Yehong Zhang, PhD, MBA**, President, Sincere Pharmaceutical Group, and many more...

This 1 credit graduate course is being offered through the Department of Medical Ethics and Health Policy (<http://www.med.upenn.edu/medicaethics/>) at the University of Pennsylvania's Perelman School of Medicine. This course carries the normal Perelman School of Medicine tuition and fees (\$5,202) as well as trip associated fees (estimated at ~\$4000, which includes all expenses related to travel to and within China, luxury accommodations, daily breakfast, tours, and Chinese visa.)

**Applications Due - May 15, 2012.**

For additional information and to apply visit <http://www.med.upenn.edu/mbe/mbechina.shtml>, email [MBEchina@mail.med.upenn.edu](mailto:MBEchina@mail.med.upenn.edu) or call 215-898-7136.